Welcome to our dedicated page for Marijuana news (Ticker: MAJI), a resource for investors and traders seeking the latest updates and insights on Marijuana stock.
MARIJUANA INC (OTCPINK: MAJI), doing business as Exousia Pro, Inc., generates a steady flow of news as a clinical-stage biotechnology company focused on exosome-based delivery systems, oncology, nutraceuticals, cannabinoids, diagnostics, and telehealth. Its announcements provide insight into how the company is advancing proprietary exosome technologies and structuring its business divisions.
News items frequently cover scientific and clinical milestones, such as the development of exosome-based therapies for malignant Glioma (Glioblastoma multiforme) and the receipt of Orphan Drug Designation from the FDA for this indication. The company also reports on technical advances like patent-pending methods for loading extracellular vesicles, successful loading of CBD into milk-derived exosomes, and planned Institutional Review Board studies to compare exosome-loaded CBD formulations with standard edibles.
Another recurring theme in MAJI news is product and market development. Exousia Pro has announced the launch of Maxasome™, an exosomal nutraceutical derived from Yellow Oyster Mushroom, and has described strategies to offer it on a subscription basis in the longevity and wellness market. The company also issues updates on licensing agreements with the University of Central Florida for exosome-based cancer diagnostics and therapies, including the planned NANOG DNA cancer screening test.
Corporate and strategic developments are also prominent in MAJI’s news feed. Releases describe the creation of the Exousia Health telehealth division, letters of intent and agreements to acquire telehealth platforms, and an all-stock transaction that gave MAJI a controlling interest in LAMY (LMMY) to advance Exousia AI as an SEC-reporting entity. Legal updates, such as court actions involving a former officer and related shareholders, appear as part of the company’s efforts to address governance and shareholder protections.
Investors and observers can use the MAJI news page to follow these scientific, commercial, licensing, telehealth, and corporate governance developments as the company reports them over time.
Exousia Pro (OTCPINK:MAJI) has successfully renegotiated its license agreement with Progenicyte of Japan, reducing the licensing fee from 50% to 30% equity position. The agreement grants worldwide licensing rights to Progenicyte's Exosome DNA loading patent and future exosome technologies.
Under the new terms, Exousia Pro will pay Progenicyte a monthly operating fee of $16,667. The patent has been filed in Japan, US, Canada, Europe, and China. Progenicyte will continue developing new exosome uses and devices exclusively licensed to Exousia Pro.
The company views this technology as important for scaling exosome manufacturing, noting that among approximately 10,000 active clinical trials, only 10 currently use exosomes. Exousia Pro aims to demonstrate the technology's potential in Glioblastoma treatment and believes it could compete with the monoclonal antibodies market, which represents over 30% of pharmaceutical sales.
Marijuana Inc. (OTCPINK: MAJI) has acquired 100% of Exousia AI in a cash and stock transaction, issuing 47 million restricted shares to Ludwig Enterprises with specific lock-up features tied to NASDAQ uplisting. The deal includes assuming liabilities under $75,000 and a $100,000 note.
The acquisition brings worldwide licensed technology for plant-based and human-derived exosomes, including ongoing studies for Glioblastoma treatment and planned studies in dermatology and dental markets. The company will manufacture and sell exosomes for nutraceutical and dermatology markets, targeting the rapidly growing cosmeceuticals sector.
The exosome skincare market is projected to grow from $310 million in 2025 to $633 million in 2033, with a 10% compound annual growth rate. A 30-day treatment currently sells for $400 per vial. The company plans to expand its oncology studies and potentially license its technology to drug manufacturers for enhanced chemotherapy treatments.